Investigation Launched Against West Pharmaceutical Services, Inc. over Alleged Securities Law Violations
NEW YORK, NY – March 18, 2025 – Levi & Korsinsky, a leading securities law firm, announced today the commencement of an investigation into West Pharmaceutical Services, Inc. (“West Pharmaceutical Services” or “the Company”) (NYSE: WST) regarding potential securities laws violations. The investigation focuses on whether the Company and its executives violated federal securities laws by making misleading statements and/or failing to disclose material information to investors.
Background
On February 12, 2025, West Pharmaceutical Services reported its fourth-quarter 2024 financial results, which showed revenue of $1.2 billion, a 5% increase year-over-year, and adjusted earnings per share of $1.75, a 12% increase year-over-year. The Company also announced that it had entered into a definitive agreement to acquire a medical device business for $1.1 billion in cash. However, the Company’s full-year 2025 guidance was well below analysts’ expectations, with projected revenue of $5.1 billion and adjusted earnings per share of $5.80, compared to the consensus estimates of $5.3 billion in revenue and $6.03 in adjusted earnings per share.
Investigation Details
Levi & Korsinsky is investigating whether West Pharmaceutical Services failed to disclose material information to investors regarding the Company’s financial condition, including any potential challenges to its revenue growth or profitability. The investigation also focuses on whether the Company’s executives made false or misleading statements regarding the Company’s business, financial condition, and prospects.
Impact on Individual Investors
If you are a shareholder of West Pharmaceutical Services: you may have standing to hold the Company harmless from the harm caused by the securities laws violations. You may also be entitled to participate in a lawsuit against the Company and its executives to recover damages for any losses sustained.
Impact on the World
The investigation and potential securities laws violations at West Pharmaceutical Services could have far-reaching consequences for the pharmaceutical industry as a whole. Investors may become more cautious when investing in pharmaceutical companies, particularly those with weak financials or questionable business practices. Regulators may also increase their scrutiny of these companies, potentially leading to increased regulatory oversight and stricter reporting requirements.
Conclusion
Levi & Korsinsky’s investigation into West Pharmaceutical Services highlights the importance of transparency and accuracy in financial reporting. Investors rely on accurate information to make informed decisions, and companies have a responsibility to provide that information. If you believe that you have suffered losses as a result of West Pharmaceutical Services’ alleged securities laws violations, please contact Levi & Korsinsky to discuss your options for recovering those losses.
The investigation is ongoing, and Levi & Korsinsky will continue to monitor the situation closely. For more information, please contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500.
- Levi & Korsinsky commences investigation into West Pharmaceutical Services, Inc.
- Company reported positive 4Q 2024 financial results but missed full-year 2025 guidance.
- Investigation focuses on potential securities laws violations.
- Individual investors may be entitled to recover losses.
- Impact on the pharmaceutical industry could be significant.
